Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Companies
Patients
Investigators
Trials & Research
Regulatory
Therapeutics
Companies
LATEST NEWS
PPD and VirtualScopics expand strategic alliance for medical imaging services
27 January 2012
PPD and VirtualScopics have expanded their one-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to now include oncology, central nervous system, cardiovascular, general medicine and medical devices. The companies deliver integrated and customised ...
Lilly exit from JV with Jubilant doesn't end commitment to FIPNet strategy
24 January 2012
Lilly and the Jubilant group have exited their equally owned Indian joint venture for early stage drug development, Vanthys, though the US multinational suggests that the decision is in no way indicative of any departure from its fully integrated pharmaceutical network strategic approach to capture ...
Quintiles invests in biomarker start-up; Glyn Edwards to head
20 January 2012
Quintiles has invested £3 million in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients. Glyn Edwards , the ex-CEO of Antisoma and the interim CEO of the BioIndustry ...
Quintiles opens Chinese BPO centre
18 January 2012
Quintiles has opened a business process outsourcing (BPO) and project management centre of excellence in Dalian, northeast China, to serve the Japanese, Chinese and South Korean biopharmaceutical markets. The Dalian office will provide data management, biostatistics, medical writing, ...
>> More Latest News...
FEATURES
Alliance strategies to increase productivity and mitigate risk
29 September 2011
While networked drug development alliances are still in their infancy, they provide an innovative approach that addresses multiple issues biopharms and CROs are dealing with in today’s R&D environment. Keith Ruark looks at how to put these alliances into action. With more than $89 billion in ...
The SCR 18: CRO league tables
29 September 2011
The CRO market is predicted to triple in the next 10 years, mainly because of increased outsourcing from big pharma as it readjusts its R&D strategy. This means a stronger magnifying glass will be placed on the largest players in the CRO market as they jostle for position to win preferred provider ...
Building core strength through financial strategy
29 September 2011
The CRO industry is full to the brim with private equity investment, with companies such as PRA International , ReSearch Pharmaceutical Services (RPS), INC Research, Medpace , Chiltern International and Theorem Clinical Research (formerly Omnicare Clinical Research ) all benefiting from the ...
Private equity flexes its clinical research muscles
29 September 2011
Private equity investors are making waves in clinical research. The most notable example of this so far has been the sale of the public CRO Kendle to its rival INC Research . Although a smaller company in terms of both revenue and headcount, INC Research has the backing of its new and active ...
>> More Features...
PEOPLE
Exco InTouch hires CTO
01 February 2012
Exco InTouch , a provider of mobile patient engagement and communication solutions has hired Madhav Vattikuti as Chief Technology Officer (CTO). Vattikuti’s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch’s market ...
Chiltern adds therapeutic experts to team
01 February 2012
The CRO Chiltern International has hired Drs Marcelo Piccirillo and Carlo Lanza to its medical teams. Dr Piccirillo will serve as senior clinical research physician with special emphasis in developing the gastroenterology therapeutic area. He has 20 years experience in the medical and clinical ...
Henauer joins i3 as head of resourcing
01 February 2012
PharmaNet/i3 , inVentiv Health’s clinical segment, has hired Dr Stephan Henauer as executive director, i3 Pharma Resourcing. In this role, Dr Henauer will provide leadership for PharmaNet/i3’s staffing business in central, eastern and northern Europe. Prior to joining PharmaNet/i3, Dr Henauer was ...
>> More People...
COMMENTARY
Deals to drive innovation for the next three billion
Deals such as ICON’s recent acquisition of BeijingWits Medical Consulting not only reflect the opportunity presented by emerging growth markets but also the need for local knowledge to conduct business effectively and tailor new product development to local market needs. We expect more deals to ...
Prepare for the regulatory revolution
Every medicine has associated side effects, or adverse drug reactions (ADRs). The European Impact Assessment Report on Pharmacovigilance (PV) estimated that approximately 5% of all hospital admissions are due to ADRs and that ADRs are the fifth most common cause of hospital death, accounting for an ...
CROs: focus on therapeutic areas for project gains
Lifestyle, living standards and longevity will all play their part in the disease profile of the future global population. Aligned with these factors is the shifting market for pharmaceuticals, an increasing proportion of profits will come from outside of the US and Europe as the developing world ...
Navigating the sea of data protection law in European clinical research
In Europe, there is a common set of rules that regulate the collection, use, and sharing of personal data. These include strict protection of sensitive data such as health data. However, individual European countries have interpreted and implemented the rules on the use of health data in clinical ...
Lean strategies for R&D partnership transformation
Lean methods for transformation, believes Deloitte 's Julian Remnant , could form a foundation for multi-company collaborations that might define the next generation of industry partnerships. In my April column, I recognised the benefits R&D organisations have realised from the first generation of ...
Delivery partners will have opportunity to shape sponsor IT strategy
Information technology investments in R&D will begin to target the ‘value analytics’ agenda, believes Deloitte 's Julian Remnant , and to do so, he suggests sponsors will increasingly draw on their delivery partners to shape operational IT strategy. The last ten years has seen industry-wide IT ...
>> More Commentary...
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Partnerships in Clinical Trials
04 March 2012
The Marriott World Center, Orlando, Florida
